protective immune response – Communicable Diseases Research

Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2

Article

Published on 2022-10-182022-11-15
Journal: PLoS ONE
[Category] COVID19(2023년), SARS, 변종, 진단, 치료기술,

[키워드] antibody antibody production appear BNT162b2 BNT162b2 mRNA vaccine convalescent correlated COVID-19 COVID-19 patients decrease detectable eight elicit functional generate Heterologous humoral humoral immune response Immunity immunization increase induce marker mRNA vaccination mRNA vaccine mucosal mucosal immune NAb Neutralizing neutralizing capacity of BNT162b2 omicron peaked progression proportion protective immune response RBD RBD-binding antibody reduced Saliva SARS-CoV-2 second dose second vaccination sera significantly Spike protein subsequent the RBD the S1 subunit the SARS-CoV-2 vaccinated individual vaccination Vaccine vaccinee vaccinees variant virus neutralizing titers VoC VOCs wildtype
[DOI] 10.1371/journal.pone.0263861 PMC 바로가기

SARS-CoV-2 reinfections with BA.1 (Omicron) variant among fully vaccinated individuals in northeastern Brazil

Article

Published on 2022-10-032022-11-16
Journal: PLoS Neglected Tropical Diseases
[Category] COVID19(2023년), SARS, 변종,

Mucosal immunity: The missing link in comprehending SARS-CoV-2 infection and transmission

Article

Published on 2022-08-172022-11-15
Journal: Frontiers in Immunology
[Category] SARS, 진단,

[키워드] accumulating acquisition acute respiratory disease Administered aerosol antibody Antibody Response asymptomatic infection cause Community consequence Contact COVID COVID-19 demonstrated disease droplet explain helping humans immune system Immunoglobulin immunoglobulin A induce Infection initial intranasally limit lung mice Mild mucosal mucosal immune mucosal immunity mucosal secretion naïve subjects nasal fluid nasal passage Prevent protective immune response recall repeated response resulting Saliva SARS-CoV-2 SARS-COV-2 infection secretion secretory IgA SIgA Spread subjects suppress tonsil Transmission Transmission. upper respiratory upper respiratory tract Vaccine virus while
[DOI] 10.3389/fimmu.2022.957107 PMC 바로가기

Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters

Tixagevimab 및 Cilgavimab(Evusheld)는 b 세포 고갈자에 대한 다발성 경화증 환자에서 SARS-CoV-2에 대한 항체 수준을 높입니다.

Article

Published on 2022-07-012022-09-12
Journal: Multiple sclerosis and related disorders
[Category] COVID19(2023년), MERS, SARS, 진단,

Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients

혈청 음성 입원 환자에서 우려 일치 COVID-19 회복기 혈장 사용의 변형

Article

Published on 2022-06-302022-09-11
Journal: Viruses
[Category] COVID19(2023년), MERS, SARS, 변종, 진단,

[키워드] 28-day mortality advanced disease Adverse reaction Adverse reactions affecting age anti-spike monoclonal antibodies anti-spike monoclonal antibody Anti-viral therapy Blood donors CCP collected convalescent convalescent plasma COVID-19 COVID-19 convalescent plasma Delta Efficacy hospital Hospitalized hospitalized COVID-19 patient hospitalized patient Immunocompromised Immunocompromised patient Immunocompromised patients infused IQR Italian mAb mAbs median age mortality rate NAbs Neutralizing antibodies neutralizing antibody omicron outcome patients protective immune response Randomized controlled trial recipient reported rescued SARS-CoV-2 seronegative severe COVID-19 Support Two patient two patients Usage variants variants of concern variants of concern. VoC VOCs were recorded
[DOI] 10.3390/v14071443 PMC 바로가기 [Article Type] Article

Antibodies to combat viral infections: development strategies and progress

Review

Published on 2022-06-202022-10-05
Journal: Nature Reviews Drug Discovery
[Category] COVID19(2023년), SARS, 변종, 임상, 진단, 치료제,

Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters

Research

Published on 2022-06-152022-10-05
Journal: Nature Microbiology
[Category] COVID19(2023년), SARS, 변종, 치료제,

Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection

MVA 기반 백신의 비강내 접종은 IgA를 유도하고 SARS-CoV-2 감염으로부터 hACE2 마우스의 호흡기를 보호합니다

Article

Published on 2022-06-142022-09-11
Journal: Proceedings of the National Academy of Sciences of
[Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술,

[키워드] acute respiratory syndrome administration Antigen Beta Blood CD3 CD8 coronavirus coronavirus 2 coronavirus vaccine COVID-19 COVID-19 pandemic current effective expressing firefly luciferase hACE2 IFN-γ IgA IgG immune responses Immunity immunized Immunoglobulin immunoglobulin A Immunoglobulin G induce Infection Infectious virus intramuscular intramuscular vaccination intramuscularly intranasal intranasally K18-hACE2 less luciferase Luminescence lung Lungs mice modified vaccinia virus morbidity mucosal mucosal immunity nasal turbinate nasal turbinates neutralized Neutralizing antibodies neutralizing antibody omicron Prevent prevented priming PROTECT protective immune response pseudovirus pseudoviruses raise remained respiratory respiratory immunity respiratory tract S protein S proteins SARS-CoV-2 SARS-COV-2 infection serum severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 severity T cells the S protein Transmission upper respiratory tract vaccination Vaccine vaccinia virus vaccinia virus. variants Viral while Wuhan
[DOI] 10.1073/pnas.2202069119 PMC 바로가기 [Article Type] Article

Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR

Research

Published on 2022-06-132022-10-05
Journal: Nature biotechnology
[Category] COVID19(2023년), SARS, 유전자 메커니즘, 임상, 치료기술,

Intranasal immunization with a proteosome-adjuvanted SARS-CoV-2 spike protein-based vaccine is immunogenic and efficacious in mice and hamsters

프로테오솜 보조제가 첨가된 SARS-CoV-2 스파이크 단백질 기반 백신을 사용한 비강내 면역은 마우스와 햄스터에서 면역원성과 효능이 있습니다.

Article

Published on 2022-06-132022-09-11
Journal: Scientific Reports
[Category] COVID19(2023년), MERS, SARS, 변종, 진단,

[키워드] addition Antigen B.1.351 B.1.617.2 Beta binding Blood body weight Body weight loss cellular Delta disease evaluated Formulation hamster help IgA titers IgG immune responses immunization immunogenic intranasal Lungs mice mucosal mucosal surface Neutralizing activity offer pandemic persistence prefusion Prevent profile protective immune response Protein protein subunit vaccine reduce reducing reference strain resistin robust SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 pandemic SARS-CoV-2 spike SARS-CoV-2 vaccine serum antibodies serum antibody spike Spike protein Subunit vaccine the SARS-CoV-2 Vaccine variants variants of concern Viral viral entry Viral load viral spike protein weight loss
[DOI] 10.1038/s41598-022-13819-5 PMC 바로가기 [Article Type] Article